NDC 50090-3576-00 - Valsartan and Hydrochlorothiazide
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50090-3576
- Requested NDC
- 50090-3576-00
- Package NDCs from labels
- 50090-3576-0, 50090-3576-00
- Manufacturer
- A-S Medication Solutions
- Effective date
- 2024-01-30
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Valsartan and Hydrochlorothiazide - A-S Medication Solutions | A-S Medication Solutions | 2024-01-30 | Human Prescription Drug Label |
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-3576-0 | Valsartan and Hydrochlorothiazide | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 10 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-3576 | VALSARTAN AND HYDROCHLOROTHIAZIDE TABLET, FILM COATED [A-S MEDICATION SOLUTIONS] | 10 | Current NDC, Legacy NDC, 1 package rows | 20240201_7b3fbdc9-d7e0-498f-a52d-e8a6b34f4a1f.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-3576-0 | EA - Each | 50090-3576 | 0cc6b273-9d5a-4e71-b5a7-97a5dba98278 | 1 | 2021-11-09 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| HERA SILKYSTAY FOUNDATION 39N1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f41120a-521a-f5ac-e063-6394a90ac021 | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 41W1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f4158f0-c743-29c2-e063-6394a90ac721 | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 43N1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f41ecb2-9fe5-ade7-e063-6294a90abc4e | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 43O1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f425415-ed84-fc33-e063-6394a90a15f7 | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 44C1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f42d960-6b86-b4cd-e063-6294a90a98f3 | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 45N1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f4326fc-b3c3-1a8b-e063-6294a90a8d9b | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 45W1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f4335c8-596f-3269-e063-6294a90a6c3d | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 46W1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f43404e-bdab-3f4b-e063-6294a90ab881 | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 47N1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f435148-dcb1-cfdf-e063-6394a90aa8b6 | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 50N1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f43610f-6c4f-dd9d-e063-6394a90ab60a | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 48N1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f4372c4-b87a-91ab-e063-6294a90a6807 | 2026-11-01 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 49C1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5f4380d1-2cf4-1fd8-e063-6394a90a0aa3 | 2026-11-01 | Warnings | 15FIX9V2JP |
| Sacubitril and Valsartan | SACUBITRIL AND VALSARTAN | Novadoz Pharmaceuticals LLC | 44db8114-622e-41f6-96a1-447d47b0267c | 2026-10-30 | Boxed warning, Warnings, Adverse reactions | 80M03YXJ7I |
| OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | REMEDYREPACK INC. | 9c68d45d-e4c8-4f6f-9ca5-faadc056e6e7 | 2026-10-29 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | St. Mary's Medical Park Pharmacy | b2d444ee-588d-37a9-e053-2a95a90ad2f1 | 2026-10-29 | Warnings, Adverse reactions | 0J48LPH2TH |
| HERA BLACK CUSHION FOUNDATION 13N1 | OCTINOXATE, TITANIUM DIOXIDE, AND ZINC OXIDE | Amorepacific Corporation | 5aff3d25-d034-0815-e063-6294a90a8664 | 2026-10-29 | Warnings | 15FIX9V2JP |
| Exforge HCT | AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE | Novartis Pharmaceuticals Corporation | 18d7820d-471f-4ee2-9ec6-25d8d27c77de | 2026-10-28 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH 80M03YXJ7I |
| Blue Lizard Sensitive SPF 50 Sunscreen | TITANIUM DIOXIDE AND ZINC OXIDE | Crown Laboratories | 32d78048-d281-1d80-e063-6394a90aec19 | 2026-10-28 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 32W1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eed2165-afc2-6958-e063-6294a90add58 | 2026-10-28 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 34O1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eedd87b-a7b1-1abc-e063-6294a90ae29e | 2026-10-28 | Warnings | 15FIX9V2JP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.